Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that members of its management team will participate in two significant investor conferences in August and September 2026, providing opportunities to discuss the company's business and engage with the investment community.
President and Chief Executive Officer Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, from 1:30 p.m. to 1:55 p.m. ET. The following month, Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16, 2026.
These appearances come at a pivotal time for Tonix, which recently received approval for TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company is leveraging its CNS commercial infrastructure to support its marketed products, including its acute migraine treatments Zembrace® SymTouch® and Tosymra®. Additionally, Tonix is exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
Beyond its commercial portfolio, Tonix is advancing a robust pipeline. The company's CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. In immunology, Tonix is developing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.
Participation in these conferences underscores Tonix's commitment to maintaining transparent communication with investors and stakeholders. The events provide a platform for the company to highlight recent milestones, discuss strategic direction, and address questions from the investment community. For more details on the company's latest news and updates, visit the company's newsroom at https://ibn.fm/TNXP.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on addressing high unmet medical needs in central nervous system (CNS) and immunology. The company's recent approval of TONMYA marks a significant advancement in fibromyalgia treatment, and its ongoing research and development efforts continue to expand its therapeutic reach.
